Patrick Lynch, M.D., at M. D. Anderson; Henry Lynch, M.D., at Creighton University in Omaha; and Ilan Kirsch, M.D., at NCI in Bethesda have an on-going phase I/II study of celecoxib in patients with hereditary nonpolyposis colon cancer syndrome. This trial is looking for insight into the biology of HNPCC and to determine the role of COX-2 in this disease.
Elisabeth Iljas Heath, M.D., and Arlene Forastiere, M.D., at Johns Hopkins University, Baltimore, have a phase II trial of celecoxib in people with Barretts esophagus, a condition believed to be caused by acid reflux into the lower esophagus. This trial is due to open in March at Hopkins and three other locations.
Anita Sabichi, M.D., at M. D. Anderson is heading a phase II/III trial of celecoxib versus placebo for people diagnosed with superficial bladder dysplasia or bladder cancer who are at high risk for recurrence.
Elmets is heading a phase II/III study of celecoxib for people with actinic keratoses, a precursor to squamous cell skin cancer.
A sixth trial a study of the use of celecoxib in men at risk for prostate cancer is in development.
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |